Graves hyperthyroidism after stopping immunosuppressive therapy in type 1 diabetic islet cell recipients with pretransplant TPO autoantibodies

Diabetes Care

Volumn 32, Issue 10, 2009, Pages 1817-1819

  Gillard, Pieter ^a,b   Huurman, Volkert ^c   Van Der Auwera, Bart ^b   Decallonne, Brigitte ^a   Poppe, Kris ^b   Roep, Bart O ^c   Gorus, Frans ^b   Mathieu, Chantal ^a   Pipeleers, Daniel ^b   Keymeulen, Bart ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; C REACTIVE PROTEIN; CYCLOSPORIN; LIOTHYRONINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROXINE;

ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; GENETIC SUSCEPTIBILITY; GRAFT REJECTION; GRAVES DISEASE; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; MAINTENANCE THERAPY; PANCREAS ISLET TRANSPLANTATION; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AUTOANTIBODIES; DIABETES MELLITUS, TYPE 1; FEMALE; GRAVES DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IODIDE PEROXIDASE; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 70349667314     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-2339     Document Type: Article

References (15)

1. Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, Secchi A, Brendel MD, Berney T, Brennan DC, Cagliero E, Alejandro R, Ryan EA, DiMercurio B, Morel P, Polonsky KS, Reems JA, Bretzel RG, Bertuzzi F, Froud T, Kandaswamy R, Sutherland DE, Eisenbarth G, Segal M, Preiksaitis J, Korbutt GS, Barton FB, Viviano L, Seyfert-Margolis V, Bluestone J, Lakey JR. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006;355:1318-1330 (Pubitemid 44465460)
2. Keymeulen B, Gillard P, Mathieu C, Movahedi B, Maleux G, Delvaux G, Ysebaert D, Roep B, Vandemeulebroucke E, Marichal M, In 't Veld P, Bogdani M, Hendrieckx C, Gorus F, Ling Z, van Rood J, Pipeleers D. Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. Proc Natl Acad Sci U S A 2006;103:17444-17449
3. Heimberg H, Nagy ZP, Somers G, De Leeuw I, Schuit FC. Complementation of HLA-DQA and -DQB genes confers susceptibility and protection to insulin-dependent diabetes mellitus. Hum Immunol 1992;33:10-17
4. Jacobson EM, Tomer Y. The genetic basis of thyroid autoimmunity. Thyroid 2007;17:949-961
5. Van Bockstaele DR, Deneys V, Philippé J, Bernier M, Kestens L, Chatelain B, De Waele M, Demanet C. Belgian consensus recommendations for flow cytometric immunophenotyping: the Belgian Association for Cytometry/Belgische Vereniging voor Cytometrie/Association Belge de Cytométrie. Acta Clin Belg 1999;54:88-98
6. Decochez K, Tits J, Coolens JL, Van Gaal L, Krzentowski G, Winnock F, Anckaert E, Weets I, Pipeleers DG, Gorus FK. High frequency of persisting or increasing isletspecific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age: the Belgian Diabetes Registry. Diabetes Care 2000;23:838-844 (Pubitemid 30414203)
7. Weetman AP, McGregor AM. Autoimmune thyroid disease: further developments in our understanding. Endocr Rev 1994;15:788-830
8. Leong KS, Wallymahmed M, Wilding J, MacFarlane I. Clinical presentation of thyroid dysfunction and Addison's disease in young adults with type 1 diabetes. Postgrad Med J 1999;75:467-470 (Pubitemid 29371518)
9. Unnikrishnan AG, Kumaravel V, Nair V, Rao A, Jayakumar RV, Kumar H, Sanjeevi CB. TSH receptor antibodies in subjects with type 1 diabetes mellitus. Ann N Y Acad Sci 2006;1079:220-225 (Pubitemid 44968727)
10. Khoruts A, Fraser JM. A causal link between lymphopenia and autoimmunity. Immunol Lett 2005;98:23-31
11. Todd A, Todd J. Graves' disease following successful treatment of severe aplastic anaemia with antilymphocyte globulin. Clin Lab Haematol 1999;21:69-70 (Pubitemid 29143413)
12. Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C, Weetman A, Hale G, Chatterjee VK, Waldmann H, Compston A. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999;354:1691-1695 (Pubitemid 29533060)
13. Gilquin J, Viard JP, Jubault V, Sert C, Kazatchkine MD. Delayed occurrence of Graves' disease after immune restoration with HAART: highly active antiretroviral therapy. Lancet 1998;352:1907-1908
14. Rieck M, Arechiga A, Onengut-Gumuscu S, Greenbaum C, Concannon P, Buckner JH. Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol 2007;179:4704-4710
15. Pearl JP, Parris J, Hale DA, Hoffmann SC, Bernstein WB, McCoy KL, Swanson SJ, Mannon RB, Roederer M, Kirk AD. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005;5:465-474 (Pubitemid 40313337)